---
layout: default
title: Sevoflurane
parent: 僅模型預測 (L5)
nav_order: 572
evidence_level: L5
indication_count: 10
---

# Sevoflurane
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Sevoflurane: From General Anesthesia to Prinzmetal Angina

## One-Sentence Summary

Sevoflurane is a volatile halogenated-ether inhalational agent used for induction and maintenance of general anesthesia. The TxGNN model predicts a possible link to **Prinzmetal angina** (coronary vasospasm), but this prediction is currently supported by **0 clinical trials** and **0 publications** — it is a pure model-generated hypothesis with no corroborating clinical or mechanistic evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | General anesthesia (induction/maintenance) — based on established pharmacology; no approved indication text is on file because the product is not marketed in Saudi Arabia |
| Predicted New Indication | Prinzmetal angina |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 (model prediction only) |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available for this record (flagged as a High-severity data gap). Based on established pharmacological knowledge, sevoflurane is a volatile general anesthetic that produces generalized CNS depression and, at anesthetic concentrations, non-specific vasodilation of coronary and systemic smooth muscle as a downstream effect of anesthetic induction.

Prinzmetal angina is caused by transient, reversible coronary artery spasm rather than fixed atherosclerotic obstruction. The TxGNN model appears to have linked sevoflurane to this indication through the drug's known coronary-vasodilating property during anesthesia. However, this is a transient, dose-dependent, intraoperative pharmacological effect — it has no established basis as a chronic therapeutic or prophylactic mechanism for recurrent coronary vasospasm.

No clinical trial or literature evidence exists to support this hypothesis (0 trials, 0 publications retrieved). The repurposing rationale explicitly notes this is a non-specific smooth-muscle effect under anesthesia, not a targeted or sustained anti-vasospastic mechanism, and should be treated as a low-confidence, exploratory signal only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Saudi Arabia Market Information

Sevoflurane has no marketing authorization on file in Saudi Arabia (total authorizations: 0; market status: Not Marketed).

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Note: Package insert warnings/contraindications are flagged as a Blocking data gap — retrieval from the official regulatory source is required before any S1 safety pre-assessment can proceed.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Prinzmetal angina signal is a pure TxGNN model output (Evidence Level L5) with zero supporting clinical trials or publications, and the underlying mechanistic link (transient intraoperative vasodilation) does not plausibly extend to chronic disease management. There is currently no basis to advance this candidate beyond hypothesis stage.

**To proceed, the following is needed:**
- Official TFDA/SFDA package insert (warnings, contraindications) — currently a Blocking data gap
- DrugBank/pharmacology-sourced mechanism of action detail — currently a High-severity data gap
- Preclinical or mechanistic studies specifically evaluating sevoflurane (or its vasodilatory pathway) in coronary vasospasm
- Any real-world or case-level evidence of sevoflurane use in Prinzmetal angina patients, if it exists, to distinguish signal from noise
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

